Shire's Adderall Patent Suit To Go On

Law360, New York (September 25, 2008, 12:00 AM EDT) -- A federal judge has kept alive Shire LLC's patent infringement allegations against Sandoz Inc. over attention-deficit hyperactivity disorder drug Adderall XR, finding that questions still remain about whether Sandoz's proposed generic falls within the claims of Shire's patents.

In a ruling issued Wednesday, Chief Judge Edward W. Nottingham of the U.S. District Court for the District of Colorado denied Sandoz's bid for summary judgment of noninfringement and tossed two of the generics maker's defenses.

Sandoz, the generics division of Novartis AG, filed an abbreviated new drug...
To view the full article, register now.